Seventeen life-science companies that once enjoyed generous Massachusetts tax breaks are now being told to pay some of that money back, after state officials concluded they did not hire as many people as they promised.
On May 26, the Massachusetts Life Sciences Center (MLSC) informed the 17 firms that their tax incentives were being clawed back because they fell short of the hiring commitments tied to those awards. The move hits both large research operations and smaller startups and will force companies to repay benefits they had already used to offset state tax bills. For state officials, the message is that these credits are conditional on job creation, not automatic subsidies.
As reported by the Boston Business Journal, the list of decertified awardees includes the Novartis Institutes for BioMedical Research and PathAI, among others. MLSC has opened recapture reviews after determining the companies did not meet the net-new-hire targets they committed to when the awards were issued. According to the Business Journal, the actions follow internal compliance checks and will require affected firms to return some or all of the credits they had claimed.
MLSC says its tax incentive program has distributed roughly $382 million in tax breaks to 273 life-science companies since 2009. The program was expanded under the Mass Leads Act to allow larger award rounds and targeted premiums tied to manufacturing, small companies and outlying counties. The Center promotes the credits as a competitive, performance-based tool to keep high-paying biotech jobs in the Commonwealth and requires recipients to retain net new hires for a multiyear period.
How recapture works
The Department of Revenue (DOR) lays out the mechanics for clawbacks in its Technical Information Release, TIR 13-6, which explains how recapture is calculated when a certified company’s results are “materially at variance” with its award commitment. In practice, MLSC can decertify a company and the DOR can add back improperly claimed credits to that company’s tax liability. That process can result in an assessed repayment, interest and a loss of refundable credit value as described in state guidance.
State watchdogs have been pressing the Center to use those tools and are now publicly applauding MLSC’s enforcement. In a letter titled “Recent Action to Reclaim Tax Incentives,” the Massachusetts Inspector General praised the Center for terminating awards where recipients failed to meet agreed-upon hiring levels and called the recapture effort “an important step of holding businesses accountable” for public incentives. The Inspector General wrote that reclaiming funds that were not earned protects taxpayer resources and reinforces program integrity.
Local context and what to watch
Supporters of the MLSC program argue that tax incentives are essential to keeping biotech investment and high-wage jobs in Massachusetts. Critics have long countered that not every award delivers the promised job numbers and that enforcement has to match the rhetoric.
For recent background on the program’s awards and stated goals, see Hoodline’s coverage of last year’s round that distributed $29.9 million to multiple companies in the Commonwealth, including a $29.9 million incentive round, and earlier reporting that flagged persistent shortfalls in job targets among some recipients.
Historical coverage has shown the program is not without controversy. Prior reporting documented instances when a significant share of awardees underperformed on hiring and raised questions about monitoring and recapture. That track record helps explain why the latest wave of decertifications is drawing attention from both watchdogs and lawmakers.
What happens next
Companies facing decertification generally receive formal notices and can pursue administrative appeals. Recapture calculations can leave firms owing money or losing refundable credit value they already monetized, a prospect that can sting even more than the original compliance review.
Tax-advisory guides and compliance experts note that recapture is often calculated pro rata against committed job targets and can involve negotiation before final collection or adjustment.
For the Commonwealth, the test now is whether tighter enforcement strengthens public confidence in a program that remains a central tool for life-science growth in Massachusetts. This story is still developing and could shift as MLSC, the Department of Revenue or affected companies release additional statements.
